Chime Biologics, a prominent Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has entered into a strategic cooperation agreement with Kings Pharm. Under this agreement, Chime Biologics will utilize its extensive expertise in biosimilar projects to provide Kings Pharm with services such as cell line development, early process development, global clinical and commercial manufacturing, and registration support. Chime Biologics will serve as the exclusive CDMO service provider and will assist Kings Pharm in bringing their asset to global markets.

The signing ceremony for this partnership was attended by delegates from various organizations, including the Consulate General of the Republic of Korea in Wuhan, the Foreign Affairs Office of Wuhan Municipal People's Government, Wuhan East Lake High-tech Development Zone, and Wuhan National Bio-Industry Base Construction Management Office. This agreement highlights the strong collaboration between both countries.

Jaehee Lee, Advisor of Kings Pharm, expressed their commitment to developing new drugs for oncology and metabolic diseases associated with aging. He emphasized their belief in respecting and preserving human life. This anti-tumor biosimilar project marks the first collaboration between Kings Pharm and Chime Biologics. Mr. Lee expressed their satisfaction in establishing a strategic partnership with Chime Biologics, citing Chime's proven track record of quality systems meeting international standards, extensive experience in biologics marketing and regulatory filing, and a flexible business model capable of ensuring global development and production for this critical project. He further noted their willingness to authorize exclusive cooperation with Chime Biologics and expressed anticipation for expanding their collaboration in the future to benefit patients.

Dr. Jimmy Wei, President of Chime Biologics, expressed his pleasure in forming a robust partnership with Kings Pharm to expedite the development and commercialization of the anti-tumor biosimilar. He highlighted Chime Biologics' strength in biosimilar programs, noting the team's successful experience in developing several biosimilars and their proprietary platform for high-expression cell line development. This platform allows Chime Biologics to offer cost-effective biosimilar development services to clients worldwide. Dr. Wei also emphasized that this collaboration marks the beginning of Chime Biologics' global one-stop solution for biosimilars, aiming to support Kings Pharm in bringing their biosimilars to market and enhancing patient access to biologics on a global scale.

Chime Biologics is launching a comprehensive one-stop solution for biosimilars, offering clients support from the initial product idea through biosimilar Investigational New Drug (IND) filing, clinical sampling, commercial manufacturing, and regulatory services.